scholarly journals MP52-20 PATIENT REPORTED OUTCOMES (PROS) IN SPARTAN, A PHASE 3, DOUBLE-BLIND, RANDOMIZED STUDY OF APALUTAMIDE (APA) PLUS ANDROGEN DEPRIVATION THERAPY (ADT) VS PLACEBO PLUS ADT IN MEN WITH NONMETASTATIC CASTRATION-RESISTANT PROSTATE CANCER (NMCRPC)

2018 ◽  
Vol 199 (4S) ◽  
Author(s):  
Eric J. Small ◽  
Fred Saad ◽  
Boris A. Hadaschik ◽  
Julie N. Graff ◽  
Paul N. Mainwaring ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Androgen Deprivation Therapy ◽  
Patient Reported Outcomes ◽  
Randomized Study ◽  
Androgen Deprivation ◽  
Castration Resistant Prostate Cancer ◽  
Phase 3 ◽  
Double Blind ◽  
Castration Resistant ◽  
Patient Reported

scholarly journals Next-generation androgen receptor inhibitors in non-metastatic castration-resistant prostate cancer

2020 ◽  
Vol 12 ◽  
pp. 175883592097813
Author(s):  
Pernelle Lavaud ◽  
Clément Dumont ◽  
Constance Thibault ◽  
Laurence Albiges ◽  
Giulia Baciarello ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Overall Survival ◽  
Androgen Receptor ◽  
Androgen Deprivation Therapy ◽  
Androgen Deprivation ◽  
Next Generation ◽  
Castration Resistant Prostate Cancer ◽  
Free Survival ◽  
Castration Resistant ◽  
Recent Advances

Until recently, continuing androgen deprivation therapy (ADT) and closely monitoring patients until evolution towards metastatic castration-resistant prostate cancer (CRPC) were recommended in men with non-metastatic CRPC (nmCRPC). Because delaying the development of metastases and symptoms in these patients is a major issue, several trials have investigated next-generation androgen receptor (AR) axis inhibitors such as apalutamide, darolutamide, and enzalutamide in this setting. This review summarizes the recent advances in the management of nmCRPC, highlighting the favourable impact of next-generation AR inhibitors on metastases-free survival, overall survival and other clinically meaningful endpoints.

Sign in / Sign up

Export Citation Format

Share Document